Marksans Pharma gains as its arm gets UK MHRA approval for Fluoxetine Oral Solution

24 Jan 2023 Evaluate

Marksans Pharma is currently trading at Rs. 65.20, up by 0.40 points or 0.62% from its previous closing of Rs. 64.80 on the BSE.

The scrip opened at Rs. 64.70 and has touched a high and low of Rs. 66.65 and Rs. 63.90 respectively. So far 203268 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 69.60 on 20-Jan-2023 and a 52 week low of Rs. 38.70 on 20-Jun-2022.

Last one week high and low of the scrip stood at Rs. 69.60 and Rs. 63.90 respectively. The current market cap of the company is Rs. 2952.36 crore.

The promoters holding in the company stood at 49.00%, while Institutions and Non-Institutions held 5.20% and 45.80% respectively.

UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Market Authorisation to Marksans Pharma’s wholly owned subsidiary Relonchem for Fluoxetine 20mg/5ml Oral Solution.

Therapeutic use of the product is for treatment of depressive illness and other mental/mood disorders. The product will be manufactured at the plant of Bell, Sons & Co. (Druggists) located at Gifford House, Slaidburn Crescent, Southport, UK.

Marksans Pharma together with its subsidiaries operates as an integrated international pharmaceutical company. The company’s business is distribution of pharmaceutical products.

Marksans Pharma Share Price

183.95 -3.95 (-2.10%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×